Literature DB >> 16863555

Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B.

Henry L-Y Chan1, Angel M-L Chim, Joseph T-F Lau, Alex Y Hui, Vincent W-S Wong, Joseph J-Y Sung.   

Abstract

OBJECTIVES: We aimed to study the predictive ability of model for end-stage liver disease (MELD) for short-term mortality in chronic hepatitis B.
METHODS: All patients admitted from 1996 to 2003 because of chronic hepatitis B and its related complications were identified by electronic search of the hospital database. MELD and Child-Turcotte-Pugh (CTP) scores on initial admissions were calculated. Cox proportional hazard model was used to determine the factors associated with mortality. The area under receiver operator characteristics curve (AUC) was used to determine the predictive abilities of the two models for 3-month and 1-yr mortalities.
RESULTS: A total of 2,073 patients was admitted because of liver-related problems and 506 patients had chronic hepatitis B-related complications. Two hundred fifty-six (51%) patients died and 16 (3%) patients underwent liver transplantation. In multivariate analysis, MELD and CTP scores were independent predictors of 3-month and 1-yr mortality. Other independent predictors of mortality included older age, hepatocellular carcinoma (HCC), lamivudine treatment, and lower serum sodium. At both 3 months and 1 yr, the AUC of the MELD score (0.65 and 0.63, respectively) was significantly lower than that of the CTP score (0.75 and 0.77, respectively) (p < 0.0001). The differences remained significant when only liver cirrhosis patients without HCC at presentation were analyzed, but the AUC of the two scores became comparable when patients on lamivudine were excluded.
CONCLUSIONS: The MELD score is a valid prognostic model in decompensated chronic hepatitis B. Lamivudine treatment may affect the performance of MELD score. Other variables including those in CTP score may improve its predictive ability.

Entities:  

Mesh:

Year:  2006        PMID: 16863555     DOI: 10.1111/j.1572-0241.2006.00659.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

1.  Antiviral therapy for acute-on-chronic liver failure in chronic hepatitis B: is it too late?

Authors:  Henry Lik-Yuen Chan
Journal:  Dig Dis Sci       Date:  2010-08       Impact factor: 3.199

2.  Influence of chronic HBV infection on superimposed acute hepatitis E.

Authors:  Si-Hong Cheng; Li Mai; Feng-Qin Zhu; Xing-Fei Pan; Hai-Xia Sun; Hong Cao; Xin Shu; Wei-Min Ke; Gang Li; Qi-Huan Xu
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

Review 3.  Organ allocation for chronic liver disease: model for end-stage liver disease and beyond.

Authors:  Sumeet K Asrani; W Ray Kim
Journal:  Curr Opin Gastroenterol       Date:  2010-05       Impact factor: 3.287

4.  Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B.

Authors:  Bingliang Lin; Calvin Q Pan; Dongying Xie; Junqiang Xie; Shibin Xie; Xiaohong Zhang; Biao Wu; Chaoshuang Lin; Zhiliang Gao
Journal:  Hepatol Int       Date:  2013-02-11       Impact factor: 6.047

5.  Model for end-stage liver disease versus the Child-Pugh score in predicting the post-transplant 3-month and 1-year mortality in a cohort of Chinese recipients.

Authors:  Zhiyong Guo; Xiaoshun He; Linwei Wu; Weiqiang Ju; Anbin Hu; Qiang Tai; Dongping Wang; Yi Ma; Guodong Wang; Xiaofeng Zhu; Jiefu Huang
Journal:  Surg Today       Date:  2009-12-29       Impact factor: 2.549

6.  Model for end-stage liver disease (MELD) score and cost-effectiveness on living donor liver transplantation.

Authors:  Takafumi Ichida; Yutaka Narita; Romi Murakami
Journal:  J Gastroenterol       Date:  2006-10       Impact factor: 6.772

7.  Comparison of the Child-Turcotte-Pugh classification and the model for end-stage liver disease score as predictors of the severity of the systemic inflammatory response in patients undergoing living-donor liver transplantation.

Authors:  Sang-Hyun Hong; Jeong-Eun Kim; Mi-La Cho; Yu-Jung Heo; Jong-Ho Choi; Jung-Hyun Choi; Jaemin Lee
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

8.  Predictive Value of the Model of End-Stage Liver Disease in Cirrhotic Patients with and without Spontaneous Bacterial Peritonitis.

Authors:  Bledar Kraja; Marsela Sina; Iris Mone; Fatjona Pupuleku; Adriana Babameto; Skerdi Prifti; Genc Burazeri
Journal:  Gastroenterol Res Pract       Date:  2012-02-22       Impact factor: 2.260

9.  Albumin-Bilirubin Score Differentiates Liver Fibrosis Stage and Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Virus Infection: A Retrospective Cohort Study.

Authors:  Koji Fujita; Takako Nomura; Asahiro Morishita; Kyoko Oura; Hirohito Yoneyama; Hideki Kobara; Kunihiko Tsutsui; Takashi Himoto; Tsutomu Masaki
Journal:  Am J Trop Med Hyg       Date:  2019-07       Impact factor: 2.345

Review 10.  Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Ying Peng; Xingshun Qi; Xiaozhong Guo
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.